Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance October 16, 2026 8:00 AM EDT
Company Participants
Brian Luque – Head of Investor Relations & Corporate Development
Harith Rajagopalan – Co-Founder, CEO, Director & Principal Executive Officer
Conference Call Participants
Adrian Dan
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Whitney Ijem – Canaccord Genuity Corp., Research Division
Nicholas Mattiacci
Chi Meng Fong – BofA Securities, Research Division
Jeffrey Cohen – Ladenburg Thalmann & Co. Inc., Research Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, everyone, and welcome to the Fractyl Health data call on the top line results from the pivotal cohort of REMAIN-1. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Fractyl Health’s website following the conclusion of the event. I’d now like to turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl Health. Please go ahead, Brian.
Brian Luque
Head of Investor Relations & Corporate Development
Thanks, Lara. Good morning, everyone, and thank you for joining us. I’m Brian Luque, Head of Investor Relations and Corporate Development at Fractyl Health. Today, we will review the positive 6-month top line results from the ongoing REMAIN-1 pivotal study of Revita in post-GLP-1 weight maintenance. Dr. Harith Rajagopalan, our Co-Founder and CEO, will discuss what these findings mean for patients, the remaining 12-month assessment and how the results advance the regulatory and commercial strategy we outlined on our September 1st Investor Day. We will take questions after the prepared remarks.
First, let me please turn to the legal disclaimer. During this presentation, we will be making forward-looking statements about future clinical results, regulatory submissions and authorizations, reimbursement, commercial launch, potential treatment populations and future catheter